PDE4A and metabolic syndrome: It is hypothesized that apremilast may have a positive impact on factors associated with MetS, such as insulin resistance and lipid metabolism [36], as PDE-4-mediated cAMP signaling has a critical role in the context of glucose and lipid metabolism [36,37].